Pharma Focus Asia

Pfizer Continues Investment in Irish Plants

US-based Pfizer is investing US$130 million into Irish plants, as part of its ongoing expansion plans. Pfizer invests US$100m into Grange Castle, west Dublin biologics unit and US$30m into Ringaskiddy plant in County Cork.

The Department of Jobs, Enterprise and Innovation through IDA Ireland, willsupport the investmentsand will support the sites to expand their capacity in producing more advanced, complex therapies to deal with some of the most dangerous and difficult to cure diseases.

The Ringaskiddy site was Pfizer’s first manufacturing facility in Ireland almost 45 years ago with an investment of more than US$7 billion in developing the skills, scale and capability necessary to manufacture some of Pfizer’s medicines in cancer and other future pipeline medicinesfor global export from Ireland.

After expansion, Grange Castle manufacturing plant will be able to double the production of its rheumatoid arthritis drug Enbrel and will also manufacture new biologics. The expanded facility is expected to be operational in 2015.

magazine-slider-imageHexagon - Expert Insights WebinarMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference